Oxford Science Enterprises (OSE) joins existing investors SV Health Investors, Lilly, Sofinnova Partners, Longwood Fund and GSKFollows original $30 million Series A raise, and brings total raised by the Company to date in excess of $75 million  Funds will be used to advance proprietary pipeline of immunometabolism-targeting therapies into clinical development Oxford, UK – 27 September 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces the successful completion of an additional financing, raising a further $39 million (£32 million), following the $30 million Series A financing announced in October 2018.

牛津科学企业（OSE）加入现有投资者SV Health投资者，礼来，Sofinnova Partners，Longwood Fund和GSK Follows original 3000万美元A系列筹集，迄今为止该公司筹集的总额超过7500万美元将用于推进免疫代谢靶向治疗的专有管道进入临床开发牛津，UK–2023年9月27日–Sitryx Therapeutics（“该公司”）是一家专注于调节细胞代谢以开发针对慢性自身免疫性和炎性疾病的疾病缓解疗法的生物制药公司，今天宣布成功完成额外融资，再筹集3900万美元（3200万英镑），继2018年10月宣布的3000万美元A系列融资之后。

New investor Oxford Science Enterprises (OSE) has joined existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund and GSK. Sitryx will use the proceeds to progress its immunometabolism-targeting therapies into clinical development. The Company is building a broad and differentiated pipeline of proprietary therapies by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.

新投资者牛津科学企业（OSE）已加入现有的医疗保健投资者SV Health投资者，礼来公司（Lilly），Sofinnova Partners，Longwood Fund和GSK。Sitryx将利用这些进展将其免疫代谢靶向治疗进展到临床开发中。该公司正在通过基于代谢变化如何调节免疫细胞功能来确定新的靶向方法，建立广泛而差异化的专有疗法渠道。

Neil Weir, Chief Executive Officer of Sitryx, said: “Immunometabolism is at the forefront of immunology research and our proprietary chemistry, deep biological insights and the work of our world leading team of immunometabolism experts is opening new avenues for the treatment of immune-mediated diseases.

Sitryx首席执行官Neil Weir说：“免疫代谢处于免疫学研究的前沿，我们专有的化学，深入的生物学见解以及我们世界领先的免疫代谢专家团队的工作正在为治疗免疫介导开辟新的途径。疾病。

Our broad pipeline of potential therapeutics that intervene in cell metabolism offers the potential to rebalance the immune system and achieve disease remission, leading to better patient outcomes. “This additional financing further v.

我们干预细胞代谢的广泛潜在治疗方法提供了重新平衡免疫系统和实现疾病缓解的潜力，从而带来更好的患者预后。“这一额外融资进一步v。